



How to Use This Document

This document is intended to summarize updates to the Wellfleet Rx National Preferred Formulary since the last formulary print version from 1/1/2021. These updates include both positive changes to existing formulary statuses and updates for newly approved medications. For all other medications not listed below, refer to the April 2021 National Preferred Formulary for information on formulary status.

**Positive Changes
Effective 4/1/2021 for All Users**

Move to Preferred Status

Antivirals	emtricitabine/tenofovir (generic for Truvada)
Cardiovascular	VASCEPA (Brand name only)

**Negative Changes
Effective 4/1/2021 for New Users
Effective 7/1/2021 for Existing Users**

Move to Non-Preferred

Miscellaneous	FRAGMIN
Inflammatory Disease	SOLIRIS

Add Prior Authorization

Lipid Disorder	DOJOLVI
Neurological Disease	RADICAVA

Add Age Limit

Opioid analgesics/cough suppressants	CODEINE PRODUCTS (UPDATE AGE LIMIT TO ≥ 18 YEARS OF AGE)
--------------------------------------	--

Add Quantity Limit

Behavior Health	INJECTABLE ANTIPSYCHOTICS
Diabetes	GLUCAGON (BAQSIMI & GVOKE)
Inflammatory Disease	BUDESONIDE (UCERIS)
Immunosuppressants	RASUVO (ST/QL ON 20 MG AND QL ON 22.5MG)

Move to Excluded (Preferred Product)

Antiviral Agents	TRUVADA (GENERIC EMTRICITABINE/TENOFOVIR)
Immunostimulating Agents	NYVEPRIA (ZIEXTENZO, FULPHILA)



**April 2021 Changes
National Preferred Formulary**

Cardiovascular	ICOSAPENT ETHYL (VASCEPA, TRIKLO)
Dermatology	MIRVASO (MINOCYCLINE) RECEDO (OTC MEDERMA)
Migraine	TREXIMET (GENERIC NAPROXEN AND SUMATRIPTAN INDIVIDUALLY)
Oncology	ZYTIGA 500 mg (ABIRATERONE 250 mg) – <i>GF only through 5/1/2021</i>
Pain Management	HYDROCODONE/APAP 10-300MG (HYDROCODONE-APAP 10-325) HYDROCODONE/APAP 5-300MG (HYDROCODONE-APAP 5-325) HYDROCODONE/APAP 7.5-300MG (HYDROCODONE-APAP 7.5-325)

Please note: The bolded medications are brands with a generic available.

RATIONALE OF CHANGES
<p><u>Trade Relations Strategy</u> Approach based on a financial review to deliver low net cost opportunities through pharmaceutical manufacture agreement strategies while taking into consideration the expected market share shift, future pipeline products, member impact and plan impact.</p>
<p><u>Low Net Cost Strategy</u> Delivering cost-efficient and clinically appropriate formulary content to meet the pharmacy benefit management needs of MedImpact clients; including appropriate development of preferred drug lists with consideration of low net cost strategies that includes MAC lists, non-pharmaceutical manufacture agreement strategies, and other cost management tools.</p>
<p><u>Clinical/Safety Strategy</u> Delivering cost-efficient and clinically appropriate formulary content to promote member safety and savings through the evaluation of scientific evidence, standards of practice, peer-reviewed medical literature, clinical practice guidelines, and guidance from the U.S. Food and Drug Administration (FDA)/Center for Disease Control (CDC).</p>
<p><u>Regulatory Update</u> Formulary/utilization management changes to comply with federal and/or state statutes, regulations, rules and policy requirements that pertain to the administration of the pharmacy benefit.</p>